At what enterprise value was HEMODIA acquired in 2025?

During the acquisition of HEMODIA by LBO FRANCE in 2025, the transaction's Enterprise Value is estimated to be in the range of 50M - 150M EUR.

When was HEMODIA acquired by LBO FRANCE?

HEMODIA was acquired by LBO FRANCE in 2025.

What was the revenue of HEMODIA at the time of the deal?

The revenue of HEMODIA at the time of the deal is estimated to be in the range of 50M - 100M EUR.

How is the data for the HEMODIA acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the HEMODIA deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://capitalfinance.lesechos.fr/deals/lbo/hemodia-passe-dans-le-giron-de-lbo-france-2156622

What is the average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026?

The average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026 is 14.3x.

← DATABASE

Home Database Healthcare & PharmaHEMODIA

03/2025

HEMODIA acquired by LBO FRANCE

FRANCE Life Sciences / Medical Devices EV 50M - 150M EUR

Context

Hemodia, a French healthcare group specializing in the production of sterile medical devices, is reorganizing its capital through a second leveraged buyout (LBO) with the investment fund LBO France. Bpifrance and Multicroissance, existing shareholders since the first LBO, are also reinvesting.

HEMODIA, which reported an EBITDA margin of in 2024, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (14.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

A French healthcare group specializing in the design, assembly, and distribution of sterile medical devices. Its expertise includes customized medical kits (care sets), dialysis connectors, and medical electronics (infusion pumps and enteral nutrition devices).

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2024

2023

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
04/2025	IK PARTNERS	STERIMED	FRANCE	Medical Consumables
04/2025	CINVEN	NUTRISENS	FRANCE	Nutrition & Dietary Supplements
03/2025	NUTRISENS	PRODIET	BRAZIL	Nutrition & Dietary Supplements
03/2025	SIPAREX	LABORATOIRE POLIDIS	FRANCE	Medical Consumables
03/2025	ZYDUS	AMPLITUDE SURGICAL	FRANCE	Implants & Prosthetics
02/2025	EURAZEO / TURENNE CAPITAL / KURMA PARTNERS	GERMITEC	FRANCE	Medical Devices
02/2025	NOVONESIS	FEED ENZYME ALLIANCE	DENMARK	Animal Health
01/2025	QUADRIVIO GROUP	MIR - MEDICAL INTERNATIONAL RESEARCH	ITALY	Diagnostic Equipment
01/2025	Animalcare Group	Randlab	AUSTRALIA	Animal Health
12/2024	NEXTSTAGE / IK PARTNERS	EUROBIO SCIENTIFIC	FRANCE	Diagnostic Equipment

REFERENCES

Valuation range: EV 50M - 150M EUR

Revenue range: 50M - 100M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of HEMODIA by LBO FRANCE are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Acquirer: lbo france